These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 21851969)

  • 1. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.
    Lind M; Fahlén M; Kosiborod M; Eliasson B; Odén A
    Thromb Res; 2012 Jan; 129(1):32-5. PubMed ID: 21851969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving Anticoagulation Measurement Novel Warfarin Composite Measure.
    Razouki Z; Burgess JF; Ozonoff A; Zhao S; Berlowitz D; Rose AJ
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):600-7. PubMed ID: 26420820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range.
    Razouki Z; Ozonoff A; Zhao S; Jasuja GK; Rose AJ
    Circ Cardiovasc Qual Outcomes; 2014 Sep; 7(5):664-9. PubMed ID: 25185245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry.
    Turk UO; Tuncer E; Alioglu E; Yuksel K; Pekel N; Ozpelit E; Vuran O; Tengiz I
    Cardiol J; 2015; 22(5):567-75. PubMed ID: 26100825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
    Wallentin L; Lopes RD; Hanna M; Thomas L; Hellkamp A; Nepal S; Hylek EM; Al-Khatib SM; Alexander JH; Alings M; Amerena J; Ansell J; Aylward P; Bartunek J; Commerford P; De Caterina R; Erol C; Harjola VP; Held C; Horowitz JD; Huber K; Husted S; Keltai M; Lanas F; Lisheng L; McMurray JJ; Oh BH; Rosenqvist M; Ruzyllo W; Steg PG; Vinereanu D; Xavier D; Granger CB;
    Circulation; 2013 Jun; 127(22):2166-76. PubMed ID: 23640971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation.
    Van Den Ham HA; Klungel OH; Leufkens HG; Van Staa TP
    J Thromb Haemost; 2013 Jan; 11(1):107-15. PubMed ID: 23088617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
    Hirano T; Kaneko H; Mishina S; Wang F; Morita S
    J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
    Lip GY; Frison L; Halperin JL; Lane DA
    J Am Coll Cardiol; 2011 Jan; 57(2):173-80. PubMed ID: 21111555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction.
    Szummer K; Gasparini A; Eliasson S; Ärnlöv J; Qureshi AR; Bárány P; Evans M; Friberg L; Carrero JJ
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28249846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
    Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients.
    Gallagher AM; Setakis E; Plumb JM; Clemens A; van Staa TP
    Thromb Haemost; 2011 Nov; 106(5):968-77. PubMed ID: 21901239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. INR variability and outcomes in patients with mechanical heart valve prosthesis.
    Labaf A; Själander A; Stagmo M; Svensson PJ
    Thromb Res; 2015 Dec; 136(6):1211-5. PubMed ID: 26558830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.
    Jones M; McEwan P; Morgan CL; Peters JR; Goodfellow J; Currie CJ
    Heart; 2005 Apr; 91(4):472-7. PubMed ID: 15772203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation.
    Gautam S; John RM; Stevenson WG; Jain R; Epstein LM; Tedrow U; Koplan BA; McClennen S; Michaud GF
    J Cardiovasc Electrophysiol; 2011 Mar; 22(3):248-54. PubMed ID: 20812929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
    Singer DE; Hellkamp AS; Piccini JP; Mahaffey KW; Lokhnygina Y; Pan G; Halperin JL; Becker RC; Breithardt G; Hankey GJ; Hacke W; Nessel CC; Patel MR; Califf RM; Fox KA;
    J Am Heart Assoc; 2013 Feb; 2(1):e000067. PubMed ID: 23525418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    Hylek EM; Go AS; Chang Y; Jensvold NG; Henault LE; Selby JV; Singer DE
    N Engl J Med; 2003 Sep; 349(11):1019-26. PubMed ID: 12968085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the risk of stroke, bleeding events, and mortality between female and male patients with atrial fibrillation during warfarin therapy.
    Penttilä T; Lehto M; Niiranen J; Mehtälä J; Khanfir H; Lassila R; Raatikainen P
    Eur Heart J Cardiovasc Pharmacother; 2019 Jan; 5(1):29-36. PubMed ID: 30052822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.